trial

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)

NCTId NCT00725075
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 215 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2008-10-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
215 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-04-10
Primary completion
2008-10-24
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
MK-8435 (Org 25935) 4-8 mgMK-8435 (Org 25935) 12-16 mg

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative — primary completion2008-10-24

Facts & assertions

4 sourced
Enrollment
215
Phase
PHASE2
Primary Completion Date
2008-10-24
Status
COMPLETED
relationships
The graph out of here
drug
MK-8435 (Org 25935) 4-8 mg
drug
MK-8435 (Org 25935) 12-16 mg
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication